Severe CPT-11-induced diarrhea in presence of FK-506 following liver transplantation for hepatocellular carcinoma

Anticancer Research

Volumn 21, Issue 6 A, 2001, Pages 4203-4206

  Gornet, Jean Marc ^a   Lokiec, Francois ^a   Duclos Vallee, Jean Charles ^a   Azoulay, Daniel ^a   Goldwasser, Francois ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

CPT 11; Glucuroconjugation; Hepatocellular cancer; Liver transplantation; SN 38; Tacrolimus; Topoisomerase I poison

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACETYLSALICYLIC ACID; IRINOTECAN; OMEPRAZOLE; TACROLIMUS; ZOPICLONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG GLUCURONIDATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; NEUTROPENIA; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DIARRHEA; DRUG INTERACTIONS; GLUCURONIDES; HUMANS; LIVER TRANSPLANTATION; TACROLIMUS;

EID: 0035569209     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Pharmacokinetics of FK506 in transplant patients
2. Clinical applications of the camptothecins
3. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials
4. Complete remission of unresectable hepatocellular carcinoma by the combination of aggressive surgery and high dose-intensity chemotherapy by CPT-11
5. Phase I and pharmacologic study of the camptothecin analog irinotecan administered every 3 weeks in cancer patients
6. High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: A feasability study
7. Simultaneous determination of camptothecin analogue irinotecan and its active metabolite SN-38 by high-performance liquid chromatography: Applications to plasma pharmacokinetic studies in cancer patients
8. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients
9. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
10. Irinotecan (CPT-11) metabolism and disposition in cancer patients
11. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients
12. Proficient metabolism of irinotecan by a human intestinal carboxylesterase
13. Metabolism of irinotecan (CPT-11) by CYP 3A4 and CYP3A5 in humans
14. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P 450 3A and drug interactions
15. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
16. Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports
17. Biliary excretion mechanism of CPT-11 and its metabolites in humans: Involvement of primary active transporters
18. Factors involved in prolongation of the terminal disposition phase of SN-38: Clinical and experimental studies
19. Metabolism and pharmacokinetics of camptothecin analogue CPT-11 in the mouse
20. In vitro metabolism of FK-506 in rat, Rabbit, and human liver microsomes: Identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism
21. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes
22. FK506 renal toxicity and lack of detectable cytochrome P-450 3A in the liver graft of a patient undergoing liver transplantation
23. Effects of FK506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro
24. Monitoring FK506 concentrations in plasma and whole blood
25. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital
26. Irinotecan therapy in adults with recurrent or progressive malignant glioma
27. A phase I study of irinotecan with pharmacokinetic modulation by cyclosporine A and phenobarbital
28. Identification of a new metabolite of CPT-11 (irinotecan). Pharmacological properties and activation to SN-38